Analysis: First FDA Biosimilar Filing

  • This page as PDF


Avalere impressions on the first FDA biosimilar filing.
Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.

1. The first FDA filing of a biosimilar is a key step to the U.S. having biosimilars. With their approval (maybe as early as 1Q15) we will learn whether or not these new market entries will provide competition in the specialty drug market and enable payers to hold down costs.

2. We expect FDA to apply the same standard of safety, purity and potency to biosimilars as to any other biologic. Also the same quality standards (cGMP) will apply.

3. FDA approval will be the next step. We have yet to see how patients and their healthcare providers will react to the availability of biosimilars .While the biosimilars first approved in the U.S. will likely be those already approved in Europe, differences in the U.S. health care system mean that adoption will follow different patterns.

4. Avalere has done extensive modelling of the market dynamics associated with introduction of biosimilars to U.S. markets. Savings to payers, providers and consumers will be contingent on market pricing of new products, provider and patient comfort with prescribing, federal and state regulatory factors and the extent of branded and biosimilar competition.


Webinar | Valuing the Patient Perspective: Patient-Centered HTA

On April 25 at 1 PM, this expert panel will address the challenge of integrating patient perspectives into value assessments, discussing implications for evidence strategy, health equity, caregiver involvement, and downstream impacts on care delivery. Learn More
Register Now
From beginning to end, our team synergy
produces measurable results. Let's work together.

Sign up to receive more insights about Regulatory Strategy and FDA Policy
Please enter your email address to be notified when new Regulatory Strategy and FDA Policy insights are published.

Back To Top